Thrombophilia is a genetic predisposition to hypercoagulable states caused by acquired
haemostasis conditions; pregnancy causes the haemostatic system to become …

Introduction International guidelines support the use of low molecular weight heparins for
the treatment of thromboembolism and thromboprophylaxis during pregnancy. However …

The current lack of knowledge about the effect of maternally administered drugs on the
developing fetus is a major public health concern worldwide. The first critical step toward …

Enoxaparin is frequently prescribed for pregnant women who are at high risk for
thromboembolic complications. We conducted a population pharmacokinetics study with 75 …

The use of low-molecular-weight heparins in pregnancy – how... : Current Opinion in
Obstetrics and Gynecology The use of low-molecular-weight heparins in pregnancy – how …

Normal pregnancy is accompanied by an increase in clotting factors. The resulting
hypercoagulable state has likely evolved to protect women from hemorrhage at the time of …

The synthetic pentasaccharide, fondaparinux, is the first of a new antithrombotic class:
selective factor Xa inhibitors. Comparative clinical trials of fondaparinux versus heparins in …

Thrombophilia, hypofibrinolysis, and polycystic ovary syndrome (PCOS) are associated with
recurrent pregnancy loss (RPL) and spontaneous abortion (SAB) alone and concurrently …

Currently unfractionated heparin (UH) and low molecular weight heparins (LMWH) are the
agents of choice for anticoagulation in pregnancy. LMWH have been used safely without …

Background Thromboembolic complications are much higher in pregnancy due to
procoagulant changes. Heparin does not cross the placenta and the use of unfractionated …